Blog Empty Image

The cryogenic vessel shall be properly labeled and color coded according to the medical gas contained in the vessel. Which of the following color-code is used for medical oxygen?

a. Yellow
b. Green
c. Gray
d. Brown


The cryogenic vessel shall be properly labeled and color coded according to the medical gas contained in the vessel. Which of the following color-code is used for medical oxygen?

a. Yellow
b. Green
c. Gray
d. Brown

Answer:Green. As used in this section, "cryogenic vessel" means an insulated metal container in the form of a cylinder or other design used to hold gases that have been liquefied by extreme reductions in temperature.
 
(C). Each cryogenic vessel subject to this section shall meet the following requirements:
 
(1). The vessel shall be properly labeled according to the medical gas contained in the vessel.
 
(2). The vessel shall be color coded as follows:
 
(a). Air - yellow;
 
(b). Carbon dioxide - gray;
 
(c). Cyclopropane - orange;
 
(d). Helium - brown;
 
(e). Nitrogen - black;
 
(f). Nitrous oxide - blue;
 
(g). Oxygen - green. The colors specified in this division shall not be used for any medical gas other than those specified in this division.


Blog Empty Image

INTERPOL has issued a global alert for a drug knows as 2.4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as a dieting and body-building aid.

The “Orange Notice” (PDF) warning about DNP was published after a woman in the United Kingdom died and a man in France was left seriously ill after taking the substance.

In the 1930s, DNP was used to boost metabolism and encourage weight loss, but it was taken out of circulation due to several deaths. Sold as a plain yellow powder, capsules, or cream, DNP is often illegally manufactured and sold via the Internet; unsafe manufacturing of the drug and potential contamination may be magnifying the dangers of taking the drug, notes INTERPOL.


INTERPOL has issued a global alert for a drug knows as 2.4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as a dieting and body-building aid. 

The “Orange Notice” (PDF) warning about DNP was published after a woman in the United Kingdom died and a man in France was left seriously ill after taking the substance. 

In the 1930s, DNP was used to boost metabolism and encourage weight loss, but it was taken out of circulation due to several deaths. Sold as a plain yellow powder, capsules, or cream, DNP is often illegally manufactured and sold via the Internet; unsafe manufacturing of the drug and potential contamination may be magnifying the dangers of taking the drug, notes INTERPOL.


Blog Empty Image

The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:

a. "Start Talking!"
b. "Minor Opioid"
c. "Opioid Consequences"
d. “Minor Consent”


The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:

a. "Start Talking!"
b. "Minor Opioid"
c. "Opioid Consequences"
d. “Minor Consent”

Answer: "Start Talking!", [Ohio Revised Code Title 37 Chapter 3719 Sec.3719.061(3)].
 
(1). As part of the prescriber's examination of the minor, assess whether the minor has ever suffered, or is currently suffering, from mental health or substance abuse disorders and whether the minor has taken or is currently taking prescription drugs for treatment of those disorders;
 
(2). Discuss with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment all of the following:
 
(a). The risks of addiction and overdose associated with the compound;
 
(b). The increased risk of addiction to controlled substances of individuals suffering from both mental and substance abuse disorders;
 
(c). The dangers of taking controlled substances containing opioids with benzodiazepines, alcohol, or other central nervous system depressants;
 
(d). Any other information in the patient counseling information section of the labeling for the compound required under 21 C.F.R. 201.57(c)(18).
 
(3). Obtain written consent for the prescription from the minor's parent, guardian, or, subject to division (E) of this section, another adult authorized to consent to the minor's medical treatment.
 
The prescriber shall record the consent on a form, which shall be known as the "Start Talking!" consent form. The form shall be separate from any other document the prescriber uses to obtain informed consent for other treatment provided to the minor. The form shall contain all of the following:
 
(a). The name and quantity of the compound being prescribed and the amount of the initial dose;
 
(b). A statement indicating that a controlled substance is a drug or other substance that the United States drug enforcement administration has identified as having a potential for abuse;
 
(c). A statement certifying that the prescriber discussed with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment the matters described in division (B)(2) of this section;
 
(d). The number of refills, if any, authorized by the prescription;
 
(e). The signature of the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment and the date of signing.


Blog Empty Image

Pharmacists in California may now provide naloxone, the medication that can help to reverse the effects of an opioid overdose, without a prescription after the California State Board of Pharmacy approved new emergency regulations (PDF).

To be eligible to dispense the drug under the new regulations, pharmacists must complete one hour of continuing education (CE) on the use of the drug, notes a press release (PDF) from the Board.

When dispensing the drug, pharmacists must screen for any hypersensitivity, and must provide the recipient with training in opioid overdose prevention, recognition, response, and on the administration of the drug.

The pharmacist must also provide the recipient a naloxone fact sheet (PDF), which has been approved by the Board.

In October 2014, NABP released a statement supporting an active role for pharmacists in increasing access to naloxone.

NABP is also active in educating consumers about prescription drug abuse and prevention through the AWARXE® Prescription Drug Safety Program, and information and educational resources on these topics are available on the program’s website.


Pharmacists in California may now provide naloxone, the medication that can help to reverse the effects of an opioid overdose, without a prescription after the California State Board of Pharmacy approved new emergency regulations (PDF).

To be eligible to dispense the drug under the new regulations, pharmacists must complete one hour of continuing education (CE) on the use of the drug, notes a press release (PDF) from the Board.

When dispensing the drug, pharmacists must screen for any hypersensitivity, and must provide the recipient with training in opioid overdose prevention, recognition, response, and on the administration of the drug.

The pharmacist must also provide the recipient a naloxone fact sheet (PDF), which has been approved by the Board.

In October 2014, NABP released a statement supporting an active role for pharmacists in increasing access to naloxone.

NABP is also active in educating consumers about prescription drug abuse and prevention through the AWARXE® Prescription Drug Safety Program, and information and educational resources on these topics are available on the program’s website.


Blog Empty Image

The patient med pak shall bear a label stating:
 
I. A serial number for the patient med pak.
 
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
 
III. The name, address, and telephone number of the dispenser.
 
a. I only
b. I and II only
c. II and III only
d. All


The patient med pak shall bear a label stating:
 
I. A serial number for the patient med pak.
 
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
 
III. The name, address, and telephone number of the dispenser.
 
a. I only
b. I and II only
c. II and III only
d. All

Answer: All, [Title 20 Code of State Regulations (CSR) 2220-2.145(2)(A)].
 
(A). The patient med pak shall bear a label stating—
 
1. The name of the patient;
 
2. A serial number for the patient med pak itself and a separate identifying serial number for each of the prescription orders for each of the drug products contained therein;
 
3. The name, strength, physical description or identification and total quantity of each drug product contained therein;
 
4. The directions for use and cautionary statements if any, contained in the prescription order for each drug product therein;
 
5. Any storage instructions or cautionary statements required by the official compendia;
 
6. The name of the prescriber of each drug product;
 
7. The date of preparation of the patient med pak and the beyond-use date assigned to the patient med pak (such beyond-use date shall be not later than sixty (60) days from the date of preparation);
 
8. The name, address, and telephone number of the dispenser; and
 
9. Any other information, statements, or warnings required for any of the drug products contained therein.


Blog Empty Image

The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.

True or False


The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.

True or False

Answer: True. The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.


Blog Empty Image

It shall be unlawful for any person to retail any poisons enumerated in schedules "A" that CONTAIN:
 
I. arsenic and its preparations
II. biniodide of mercury
III. cyanide of potassium

a. I only
b. I and II only
c. All
d. None of the above


It shall be unlawful for any person to retail any poisons enumerated in schedules "A" that CONTAIN:
 
I. arsenic and its preparations
II. biniodide of mercury
III. cyanide of potassium

a. I only
b. I and II only
c. All
d. None of the above

Answer: None of the above - all choices can be sold at retail, [Missouri Revised Statutes (MRS) Chapter 338 Sections 338.090].
 
It shall be unlawful for any person to retail any poisons enumerated in schedules "A" and "B", EXCEPT AS FOLLOWS:
 
Schedule "A" arsenic and its preparations, biniodide of mercury, cyanide of potassium, hydrocyanic acid, strychnia, and all other poisonous vegetable alkaloids and their salts, and the essential oil of bitter almonds.
 
Schedule "B" opium and its preparations, except paregoric and other preparations of opium containing less than two grains to the ounce, aconite, bella donna, colchicum, conium, nux vomica, henbane, savin, ergot, cotton root, cantharides, creosote, veratrum, digitalis, and their pharmaceutical preparations, croton oil, chloroform, chloral hydrate, sulphate of zinc,  corrosive sublimate, red precipitate, white precipitate, mineral acids, carbolic acid, oxalic acid, without labeling the box, vessel or paper in which the said poison is contained, and also the outside wrapper or cover with the name of the article, the word "poison" and the name and place of business of the seller.
 
Nor shall it be lawful for any person to sell or deliver any poisons enumerated in schedules "A" and "B" unless, upon due inquiry, it is found that the purchaser is aware of its poisonous character and represents that it is to be used for legitimate purposes.
 
Nor shall it be lawful for any registered pharmacists to sell any poisons included in schedule "A" without, before delivering the same to the purchaser, causing an entry to be made in a book kept for that purpose, stating
 
a. the date of sale, name and address of purchaser,
b. the name of the poison sold,
c. the purpose for which it was represented by the purchaser to be required and
d. the name of the dispenser.
 
Such book to be always open for inspection by the proper authorities, and to be preserved for at least five years.
 
The provisions of this section shall not apply to the dispensing of poison in not unusual quantities or doses upon the prescription of practitioners of medicine.



Blog Empty Image

Within the electronic supervision environment, the data entry can be performed by the pharmacy student or pharmacy technician being electronically supervised.

True or False



Within the electronic supervision environment, the data entry can be performed by the pharmacy student or pharmacy technician being electronically supervised.

True or False

Answer: True, [Kansas Pharmacy Practice Act Article 22 Sec. 68-22-5(c)].
 
(a). A pharmacy student or pharmacy technician may enter the pharmacy without a pharmacist present for purposes of turning on the data, video, or audio links and determining if a pharmacist is available for electronic supervision.
 
(b). Electronic supervision shall not be permitted if an interruption occurs in any of the data, video, or audio links. Whenever an interruption in any of the data, video, or audio links occurs, no medication order shall be filled or dispensed using electronic supervision.
 
(c). Data entry may be performed by the electronically supervising pharmacist or the pharmacy student or pharmacy technician being electronically supervised. Each entry performed by an electronically supervised pharmacy student or pharmacy technician shall be verified by the electronically supervising pharmacist before the drug leaves the pharmacy.
 
(d). All medication orders processed by a pharmacy student or a pharmacy technician being electronically supervised shall be capable of being displayed on a computer terminal at both the location of the electronically supervising pharmacist and the medical care facility's pharmacy.
 
(e). The quality of the image viewed by the pharmacist shall be sufficient for the pharmacist to be able to determine the accuracy of the work of the pharmacy student or pharmacy technician.


Blog Empty Image

The Kansas Pharmacy Board is authorized to provide data in the prescription monitoring program to the:
 
I. An individual who requests the individual's own prescription monitoring information.
 
II. Designated representatives from the department of health and environment regarding authorized Medicaid program recipients.
 
III. Persons authorized to prescribe or dispense scheduled substances and drugs of concern, for the purpose of providing medical or pharmaceutical care for their patients.
 
a. I only
b. I and II only
c. II and III only
d. All


The Kansas Pharmacy Board is authorized to provide data in the prescription monitoring program to the:
 
I. An individual who requests the individual's own prescription monitoring information.
 
II. Designated representatives from the department of health and environment regarding authorized Medicaid program recipients.
 
III. Persons authorized to prescribe or dispense scheduled substances and drugs of concern, for the purpose of providing medical or pharmaceutical care for their patients.
 
a. I only
b. I and II only
c. II and III only
d. All

Answer: (d) All, [Kansas Pharmacy Practice Act Article 16 Chapter 65 Sec. 65-1685(c)].
 
The board is hereby authorized to provide data in the prescription monitoring program to the following persons:
 
(1). Persons authorized to prescribe or dispense scheduled substances and drugs of concern, for the purpose of providing medical or pharmaceutical care for their patients;
 
(2). an individual who requests the individual's own prescription monitoring information in accordance with procedures established by the board;
 
(3). designated representatives from the professional licensing, certification or regulatory agencies charged with administrative oversight of those persons engaged in prescribing or dispensing of scheduled substances and drugs of concern;
 
(4). local, state and federal law enforcement or prosecutorial officials engaged in the administration, investigation or enforcement of the laws governing scheduled substances and drugs of concern subject to the requirements in K.S.A. 22-2502 and amendments thereto;
 
(5). designated representatives from the department of health and environment regarding authorized Medicaid program recipients;
 
(6). persons authorized by a grand jury subpoena, inquisition subpoena or court order in a criminal action;
 
(7). personnel of the prescription monitoring program advisory committee for the purpose of operation of the program;
 
(8). personnel of the board for purposes of administration and enforcement of this act or the uniform controlled substances act, K.S.A. 65-4101 et seq., and amendments thereto.
 
(9). persons authorized to prescribe or dispense scheduled substances and drugs of concern, when an individual is obtaining prescriptions in a manner that appears to be misuse, abuse or diversion of scheduled substances or drugs of concern; and
 
(10). medical examiners, coroners or other persons authorized under law to investigate or determine causes of death.


Blog Empty Image

If in the pharmacist’s professional judgment oral counseling is not practicable, the pharmacist may use alternative forms of patient information. “Not practicable” includes patient variables such as:
 
I. the patient’s or caregiver’s hearing impairment
 
II. high prescription volume
 
III. inadequate staffing
 
a. I only
b. I and II only
c. II and III only
d. All



If in the pharmacist’s professional judgment oral counseling is not practicable, the pharmacist may use alternative forms of patient information. “Not practicable” includes patient variables such as:
 
I. the patient’s or caregiver’s hearing impairment
 
II. high prescription volume
 
III. inadequate staffing
 
a. I only
b. I and II only
c. II and III only
d. All

Answer: I only.
 
If in the pharmacist’s professional judgment oral counseling is not practicable, the pharmacist may use alternative forms of patient information. “Not practicable” refers to patient variables including, but not limited to,
 
a. the absence of the patient or patient’s caregiver,
 
b. the patient’s or caregiver’s hearing impairment, or a language barrier.
 
“Not practicable” does NOT include pharmacy variables such as inadequate staffing, technology failure, or high prescription volume.
 
Alternative forms of patient information may include written information leaflets, pictogram labels, video programs, or information generated by electronic data processing equipment.
 
When used in place of oral counseling, alternative forms of patient information shall advise the patient or caregiver that the pharmacist may be contacted for consultation in person at the pharmacy by toll-free telephone or collect telephone call.
 
A combination of oral counseling and alternative forms of counseling is encouraged.





Free USA Shipping! No Minimum Order.
Free International Shipping! Over $200 or More.